[go: up one dir, main page]

NO20092586L - A-beta antistoff parenteral formulering - Google Patents

A-beta antistoff parenteral formulering

Info

Publication number
NO20092586L
NO20092586L NO20092586A NO20092586A NO20092586L NO 20092586 L NO20092586 L NO 20092586L NO 20092586 A NO20092586 A NO 20092586A NO 20092586 A NO20092586 A NO 20092586A NO 20092586 L NO20092586 L NO 20092586L
Authority
NO
Norway
Prior art keywords
parenteral formulation
beta antibody
beta
antibody parenteral
antibody
Prior art date
Application number
NO20092586A
Other languages
English (en)
Inventor
Pierre Goldbach
Hanns-Christian Mahler
Robert Mueller
Christine Wurth
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39190366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092586(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20092586L publication Critical patent/NO20092586L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sammendrag Det beskrives en stabil, farmasøytisk parenteral formulering av et antistoff, antistoff molekyl, en blanding av antistoffer og/eller en blanding av antistoff molekyler mot amyloid-beta peptidet (A-beta). Det beskrives videre en fremgangsmåte for fremstilling derav. Videre beskrives anvendelse av de oppnådde produkter.
NO20092586A 2006-12-11 2009-07-07 A-beta antistoff parenteral formulering NO20092586L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06025590 2006-12-11
PCT/EP2007/010825 WO2008071394A1 (en) 2006-12-11 2007-12-11 Abeta antibody parenteral formulation

Publications (1)

Publication Number Publication Date
NO20092586L true NO20092586L (no) 2009-07-17

Family

ID=39190366

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092586A NO20092586L (no) 2006-12-11 2009-07-07 A-beta antistoff parenteral formulering

Country Status (21)

Country Link
US (1) US20110070225A1 (no)
EP (1) EP2094729A1 (no)
JP (1) JP2010512356A (no)
KR (1) KR20090104017A (no)
CN (1) CN101553504A (no)
AR (1) AR064220A1 (no)
AU (1) AU2007331712A1 (no)
BR (1) BRPI0721097A2 (no)
CA (1) CA2671968A1 (no)
CL (1) CL2007003583A1 (no)
CR (1) CR10823A (no)
EC (1) ECSP099403A (no)
IL (1) IL198963A0 (no)
MA (1) MA30975B1 (no)
MX (1) MX2009006199A (no)
NO (1) NO20092586L (no)
PE (1) PE20081477A1 (no)
RU (1) RU2009126420A (no)
TW (1) TW200831133A (no)
WO (1) WO2008071394A1 (no)
ZA (1) ZA200904014B (no)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
JP5145241B2 (ja) * 2005-12-12 2013-02-13 エフ．ホフマン−ラ ロシュ アーゲー 可変領域におけるグリコシル化を有するアミロイドβに対する抗体
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SG10201505369QA (en) 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
ES2759075T3 (es) 2008-03-14 2020-05-07 Biocon Ltd Un anticuerpo monoclonal y un método del mismo
JP6146949B2 (ja) * 2008-06-20 2017-06-21 ノバルティス アーゲー 凝集が低減された免疫グロブリン
MX2011002402A (es) * 2008-09-19 2011-04-05 Hoffmann La Roche Formulacion de anticuerpo novedosa.
EP2346900A1 (en) 2008-10-29 2011-07-27 Wyeth LLC Methods for purification of single domain antigen binding molecules
MX345226B (es) * 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
MX2011005051A (es) * 2008-11-17 2011-06-01 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
EP2501408B1 (en) * 2009-11-20 2020-05-27 Biocon Limited Formulations of antibody
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US9795674B2 (en) 2010-02-26 2017-10-24 Novo Nordisk A/S Stable antibody containing compositions
SI2542257T1 (en) 2010-03-01 2018-01-31 Bayer Healthcare Llc Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
MX2012009460A (es) 2010-03-03 2012-09-12 Boehringer Ingelheim Int Polipeptidos biparatopicos de union abeta.
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CA2800188A1 (en) 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
WO2012028683A1 (en) * 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
WO2012151199A1 (en) 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2012250872B2 (en) * 2011-05-02 2017-07-13 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
HK1198689A1 (en) * 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
WO2013131866A1 (en) * 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Abeta antibody formulation
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP2830658B1 (en) * 2012-03-26 2018-10-10 Sanofi Stable igg4 binding agent formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
EP2968538A1 (en) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Anti-prolactin receptor antibody formulations
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
US20160114000A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN104946616A (zh) * 2015-05-12 2015-09-30 骏实生物科技(上海)有限公司 一种用于体外诊断试剂的通用固体稳定剂及其使用方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
EP3352790A1 (en) * 2015-09-22 2018-08-01 Pfizer Inc Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
KR20250007038A (ko) 2015-10-02 2025-01-13 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN106620691B (zh) * 2015-11-04 2020-08-21 信达生物制药(苏州)有限公司 一种重组全人源抗ctla-4单克隆抗体制剂及其应用
SG11201804961UA (en) 2015-12-30 2018-07-30 Genentech Inc Formulations with reduced degradation of polysorbate
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
JP7071974B2 (ja) 2016-10-21 2022-05-19 バイオコン・リミテッド モノクローナル抗体および狼瘡の処置のための使用の方法
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用
CN110352201A (zh) 2017-04-03 2019-10-18 免疫医疗公司 用于癌症疗法的抗体药物缀合物的皮下施用
EP3672631B9 (en) * 2017-08-22 2023-06-28 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
CN108373494A (zh) * 2018-02-27 2018-08-07 武汉伊艾博科技有限公司 一种防止重组蛋白质降解的保护技术
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
CN113116812A (zh) * 2019-12-30 2021-07-16 百奥泰生物制药股份有限公司 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用
WO2022072255A1 (en) * 2020-09-30 2022-04-07 Merck Sharp & Dohme Corp. Binding proteins and antigen binding fragments thereof that bind abeta
US20240417451A1 (en) 2023-05-31 2024-12-19 Hoffmann-La Roche Inc. Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
CN117088974B (zh) * 2023-08-14 2024-02-13 武汉健昊生物科技有限公司 一种抗体保存液

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE60235013D1 (de) * 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP3178492A1 (en) * 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
DOP2006000022A (es) * 2005-01-28 2006-08-15 Wyeth Corp Formulaciones líquidas estabilizadas de polipetidos
JP5145241B2 (ja) * 2005-12-12 2013-02-13 エフ．ホフマン−ラ ロシュ アーゲー 可変領域におけるグリコシル化を有するアミロイドβに対する抗体
EP1998806A1 (en) * 2006-03-28 2008-12-10 F. Hoffmann-Roche AG Anti-igf-1r human monoclonal antibody formulation

Also Published As

Publication number Publication date
IL198963A0 (en) 2011-08-01
MX2009006199A (es) 2009-06-22
WO2008071394A1 (en) 2008-06-19
PE20081477A1 (es) 2008-10-18
RU2009126420A (ru) 2011-01-20
US20110070225A1 (en) 2011-03-24
EP2094729A1 (en) 2009-09-02
TW200831133A (en) 2008-08-01
ECSP099403A (es) 2009-07-31
MA30975B1 (fr) 2009-12-01
CR10823A (es) 2009-08-12
AR064220A1 (es) 2009-03-18
AU2007331712A1 (en) 2008-06-19
CA2671968A1 (en) 2008-06-19
CN101553504A (zh) 2009-10-07
BRPI0721097A2 (pt) 2014-07-01
ZA200904014B (en) 2010-04-28
KR20090104017A (ko) 2009-10-05
CL2007003583A1 (es) 2008-07-18
AU2007331712A2 (en) 2009-07-30
JP2010512356A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
NO20092586L (no) A-beta antistoff parenteral formulering
Brik et al. Sugar-assisted glycopeptide ligation
Renaudet et al. Chemoselectively template-assembled glycoconjugates as mimics for multivalent presentation of carbohydrates
Dudkin et al. Toward fully synthetic carbohydrate-based HIV antigen design: on the critical role of bivalency
Ni et al. Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins
AR054474A1 (es) Formulacion de anticuerpos estables
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
TNSN07069A1 (en) Process for concentration of antibodies and therapeutic products thereof
WO2019170710A3 (en) Chemoselective thiol-conjugation with alkene or alkyne-phosphonothiolates and -phosphonates
Norberg et al. Photo-click immobilization on quartz crystal microbalance sensors for selective carbohydrate− protein interaction analyses
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
PE20091388A1 (es) Moleculas y metodos para modular el componente de complemento
EP4382167A3 (en) Compounds comprising a linker for increasing transcyclooctene stability
WO2006016168A3 (en) Sialic acid derivatives
Freichel et al. Sequence‐Defined Heteromultivalent Precision Glycomacromolecules Bearing Sulfonated/Sulfated Nonglycosidic Moieties Preferentially Bind Galectin‐3 and Delay Wound Healing of a Galectin‐3 Positive Tumor Cell Line in an In Vitro Wound Scratch Assay
WO2012109383A3 (en) Method of determining protein binding characteristics of a drug candidate
Li et al. Recognization of receptors on bone marrow-derived dendritic cells bound with Pholiota nameko polysaccharides
Okamoto et al. Efficient substitution reaction from cysteine to the serine residue of glycosylated polypeptide: repetitive peptide segment ligation strategy and the synthesis of glycosylated tetracontapeptide having acid labile sialyl-TN antigens
Niño-Ramírez et al. Evidence of isomerization in the michael-type thiol-maleimide addition: click reaction between L-cysteine and 6-maleimidehexanoic acid
WO2008028934A8 (en) Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
Dong et al. Investigation of N-glycan functions in receptor for advanced glycation end products V domain through chemical glycoprotein synthesis
Li et al. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein
Rozbesky et al. Structural model of lymphocyte receptor NKR-P1C revealed by mass spectrometry and molecular modeling
Koniev et al. MAPN: First-in-class reagent for kinetically resolved thiol-to-thiol conjugation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application